FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年5月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | | | | | 於香港聯交所上市 | | 是 | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | ...

Core Viewpoint - The announcement highlights the upcoming presentation of the first human Phase 1 clinical study design for the novel targeted antibody-drug conjugate (ADC) MesoC2 (HBM9033/PF-08052666) at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, in collaboration with Pfizer [1] Group 1 - MesoC2 was initially developed by the company's wholly-owned subsidiary, Nona Bioscience, utilizing its proprietary Harbour Mice platform and integrated ADC platform, and was licensed to Pfizer through a global agreement in December 2023 [1] - The ADC is currently undergoing a Phase 1 open-label study targeting various advanced solid tumor patients [1] - Pfizer will present clinical research information at the ASCO annual meeting, including a study assessing the safety and tolerability of MesoC2 in advanced solid tumor patients, with the abstract number TPS3163 and poster number 475a [1] Group 2 - MesoC2 has demonstrated significant anti-tumor efficacy in in vitro tests and xenograft models, showing acceptable safety characteristics in cynomolgus monkeys [2] - The Phase 1 trial (NCT06466187) will be conducted with dose escalation, dose optimization, and cohort expansion, evaluating up to 365 patients for MesoC2's safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy based on RECIST v1.1 criteria [2]

（於開曼群島註冊成立的有限公司） （股份代號：02142） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited 自願公告 MESOC2首次人體1期臨床研究設計於2025年ASCO年會發表 茲提述和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）日期為 2023年12月15日之公告（「該公告」）。 本公告乃由本公司自願作出，以告知本公司股東及潛在投資者有關本集團最新的 業務進展。 本公司董事會（「董事會」）欣然宣佈，輝瑞（本集團之合作夥伴）將於2025年美國 臨床腫瘤學會(ASCO)年會上發表同類首創靶向間皮素(MSLN)之抗體偶聯藥物 (ADC) MesoC2 (HBM9033/PF-08052666)的首次人體1期臨床研究設計。 MesoC2最初由本公司全資附屬公司諾納生物（蘇州）有限公司（「諾納生物」）利用 其專有的Harbour Mice®平台及一體化ADC平台自主研發， ...

FF305 呈交日期： 2025年5月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | | | | | 是 | | | 證券代號 (如上市) 02142 | 說明 | | | | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Core Viewpoint - HSBC forecasts a 3.8% year-on-year growth in A-share earnings for Q1 2025, led by the materials (+40.3%) and information technology (+24.7%) sectors, with a continued outperformance of growth style over the market [1][2] Investment Themes Artificial Intelligence (AI) - The penetration rate of AI is rising, with 68% of A-share companies mentioning "AI" in their 2024 annual reports, up from 43% in the first half of 2024 [3] - Market expectations indicate accelerated profit growth in the AI value chain for 2025, with infrastructure companies expected to grow faster than technology enablers and applicators [3] Globalization - Recent breakthroughs in US-China trade negotiations serve as a catalyst for globalization-themed stocks [4] - In 2024, overseas revenue accounted for 11.7% of total revenue for CSI 300 constituents, an increase of 1.4 percentage points year-on-year, with the information technology sector having the highest overseas revenue share at 31.4% [4] Cyclical Recovery - Cyclical industries are expected to see profit improvements, with overall earnings projected to grow by 18.8% in Q1 2025, compared to a decline of 17.9% in Q3 2024 [5] - Factors contributing to structural opportunities in cyclical industries include steady policy rollout, structural recovery in the real estate market, and attractive valuations [5] Recommended Stocks - Based on the three investment themes and bottom-up research, HSBC recommends the following 10 stocks with buy ratings: - AI Theme: Xiaomi Group-W (01810), Deepin Technology (300454.SZ), Zhangqu Technology (300315.SZ) [6] - Globalization Theme: HAPO (02142), Luxshare Precision (002475.SZ), Anker Innovations (300866.SZ), Giant Star Technology (002444.SZ) [6] - Cyclical Recovery Theme: Suzhou Bank (002966.SZ), Proya Cosmetics (603605.SH), SF Holding (002352.SZ) [6]

Summary of Key Points Core Viewpoint - On May 19, 38 Hong Kong-listed companies conducted share buybacks, totaling 38.39 million shares and an aggregate amount of HKD 831 million [1][2]. Group 1: Buyback Details - Tencent Holdings repurchased 979,000 shares for HKD 500 million, with a highest price of HKD 516.50 and a lowest price of HKD 503.00, bringing its total buyback amount for the year to HKD 21.53 billion [1][2]. - AIA Group repurchased 2.34 million shares for HKD 154 million, with a highest price of HKD 66.40 and a lowest price of HKD 64.75, totaling HKD 8.93 billion in buybacks for the year [1][2]. - China COSCO Shipping repurchased 5.56 million shares for HKD 79.36 million, with a highest price of HKD 14.40 and a lowest price of HKD 14.12, accumulating HKD 3.83 billion in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on May 19 was from Tencent Holdings at HKD 500 million, followed by AIA Group at HKD 154 million [1][2]. - In terms of share quantity, the largest buyback was conducted by Jieli Trading at 9.18 million shares, followed by China COSCO Shipping at 5.56 million shares and NetEase Technology at 4.67 million shares [1][2]. Group 3: Additional Buyback Information - Country Garden Services conducted its first buyback of the year, while Tencent Holdings has made multiple buybacks totaling HKD 21.53 billion [2][3]. - A detailed table of buybacks on May 19 includes various companies, their respective buyback shares, amounts, highest and lowest prices, and cumulative buyback amounts for the year [2][3].

| 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年5月16日 | | 832,037,122 | | 14,173,000 | | | 846,210,122 | | 1). 購回股份 (股份被持作庫存股份) | | | -450,000 | 0.054 % | 450,000 HKD | | 9.024 ...

证券时报·数据宝统计显示，5月16日有36家香港上市公司进行了股份回购，合计回购2589.39万股，回购 金额2.78亿港元。 友邦保险回购数量200.00万股，回购金额1.32亿港元，回购最高价为66.200港元，最低价为65.450港元， 年内累计回购金额87.72亿港元；中远海控回购数量556.00万股，回购金额7776.21万港元，回购最高价 为14.120港元，最低价为13.760港元，年内累计回购金额37.52亿港元；时代电气回购数量75.01万股，回 购金额2466.97万港元，回购最高价为32.900港元，最低价为32.800港元，年内累计回购金额12.73亿港 元。 以金额进行统计，5月16日回购金额最多的是友邦保险，回购金额为1.32亿港元；其次是中远海控，回 购金额为7776.21万港元；回购金额居前的还有时代电气、中国东方航空股份等。回购数量上看，5月16 日回购股数最多的是嬴集团，当日回购量为600.00万股；其次是中远海控、中国东方航空股份等，回购 数量分别为556.00万股、250.00万股。 值得关注的是，华检医疗本次回购为年内首次进行回购。本次回购1.32亿港元的友邦保险，年 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年5月16日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | ...

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的 ...